⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HALO News
Halozyme Therapeutics, Inc.
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
prnewswire.com
HALO
Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
prnewswire.com
HALO
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
prnewswire.com
HALO
Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s
prnewswire.com
HALO